Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.39 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14992876 | 1.00 | PRMT6 (0.41) | PRMT6ADORA3NR2F2ABL1RIN1 | |
| SCHEMBL14992874 | 0.90 | PRMT6 (0.41) | PRMT6ADORA3NR2F2ABL1RIN1 | |
| SCHEMBL14968139 | 0.90 | PRMT6 (0.41) | PRMT6ADORA3NR2F2ABL1RIN1 | |
| SCHEMBL29528086 | 0.88 | ABL1 (0.50) | ADORA3NR2F2ABL1RIN1ADORA1 | |
| SCHEMBL29577117 | 0.88 | ABL1 (0.50) | ADORA3NR2F2ABL1RIN1ADORA1 | |
| SCHEMBL14980421 | 0.88 | ABL1 (0.50) | ADORA3NR2F2ABL1RIN1ADORA1 | |
| SCHEMBL16207829 | 0.88 | ABL1 (0.50) | ADORA3NR2F2ABL1RIN1ADORA1 | |
| SCHEMBL19953997 | 0.87 | PRMT6 (0.43) | PRMT6NR2F2ABL1RIN1P2RY12 | |
| SCHEMBL27157760 | 0.86 | ABL1 (0.41) | PRMT6NR2F2ABL1RIN1P2RY12 | |
| SCHEMBL31614395 | 0.85 | NPC1 (0.43) | PRMT6ADORA3ADORA1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-20160376587-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| EP-2780299-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | Sarepta Therapeutics, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013074834-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | RTCB, NSUN3, NSUN2 | PRMT6 1371/4885ADORA3 3836/4885NR2F2 2485/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | PRMT6 1371/4885ADORA3 3836/4885NR2F2 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.